GlassScriptPhysician profile
Wei Zhao
NPI 1669587929
$4,575.00
in general payments reported to CMS, 2019-2025
21 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2021: $32.52 · 2022: $401 · 2023: $1,050 · 2024: $1,291 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,916 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,916.27 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,126.55 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,091.11 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $685.93 | 2019-2025 | Nucala |
| Blueprint Medicines Corporation | $291.02 | 2022-2024 | Ayvakit |
| Greer Laboratories, INC. | $175.21 | 2025 | Palforzia |
| Biocryst US Sales Co., LLC | $168.04 | 2024 | Orladeyo |
| Genentech USA, INC. | $143.04 | 2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $123.49 | 2025 | Neffy |
| Genzyme Corporation | $121.24 | 2024 | |
| Pfizer INC. | $120.47 | 2025 | |
| Neurelis, INC. | $111.23 | 2025 | Valtoco |
| Pharming Healthcare, INC. | $100.33 | 2023 | Ruconest |
| Merck Sharp & Dohme LLC | $75.00 | 2022 | |
| Ionis Pharmaceuticals, INC. | $49.96 | 2025 | Dawnzera |
| Idorsia Pharmaceuticals US INC | $40.57 | 2022-2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $33.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.52 | 2021 | |
| Calliditas Therapeutics US INC. | $30.24 | 2022 | |
| Lilly USA, LLC | $23.95 | 2024 | Jardiance |
| Dexcom, INC. | $19.73 | 2024 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.